Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
|Videos|June 30, 2021
Medical World News® Deep Dive: Expert Talks FDA Approval of Amivantamab to Treat NSCLC With EGFR Exon 20 Insertion Mutations
Author(s)Matthew Fowler
Joshua Sabari, MD, discussed the approval of amivantiamab as therapy for patients with non–small cell lung cancer harboring EGFR exon 20 insertion mutations.
Advertisement
In this episode of Deep Dive from the
Sabari detailed the challenges of treating tumors with this mutation and compared amivantamab with the other systemic therapy options in this setting. He also discusses what the future might have in store for amivantamab in this specific disease.
Advertisement
Related to this article
Matthew Lee, MD, discusses the first clinical data for BG-C477, a CEACAM5-targeting ADC, in advanced NSCLC.
Matthew Lee, MD, shares his key takeaway from the first disclosure of BG-C477 data in advanced NSCLC.
Matthew Lee, MD, discusses how confident he is that CEACAM5 expression will hold up as a biomarker for BG-C477 in NSCLC.
In the real-world CEMI-LUNG study, first-line cemiplimab produced survival and response outcomes consistent with the pivotal EMPOWER-Lung 1 trial.
Data from the phase 3 OptiTROP-Lung06 trial may support sacituzumab tirumotecan plus pembrolizumab as a new frontline option for this NSCLC population.
Data from the real-world CEMI-LUNG evaluating cemiplimab in advanced NSCLC were consistent with reports from the EMPOWER-Lung1 study.
Jesus Corral Jaime, MD, reviews real-world survival and response data for cemiplimab monotherapy from the CEMI-LUNG study.
Advertisement
Advertisement
Trending on CancerNetwork
1
Petosemtamab/Pembrolizumab Improves OS in First-Line PD-L1–Positive HNSCC
2
Sacituzumab Govitecan PFS Benefit Holds Across Subgroups in Untreated mTNBC
3
Can a Selinexor Quadruplet Treat Myeloma After T-Cell Redirecting Therapy?
4
Breast Cancer Locator Noninferior to Wire Localization for Lumpectomy Margins
5